Melbourne, Australia; 8 April 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). [Read more…]
Regenerative Applications Of Placental Tissue Allografts With Dr. Bruce Werber
I had the privilege of speaking with Dr. Bruce Werber about the innovative use of placental tissue allografts in regenerative medicine. With 35 years of experience as a board-certified foot and ankle surgeon, Dr. Werber also serves as the COO of BioTech Products, Services, and Research (BPSR) and the CEO of its subsidiary, Anu Life Sciences.
Stem Cells Surpass Landmark Milestone of 500K Scientific Publications
Wow, a tremendous achievement has been accomplished by the stem cell community. We have officially surpassed 500,000 publications about stem cells on PubMed.gov! PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature. It is the largest and most comprehensive global database that exists for scientific publications anywhere in the world. [Read more…]
Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients
SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]
Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease
Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).
Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.
Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 201
- Next Page »